CompletedPhase 1NCT05715736
Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APB-R3
Studying Adult-onset Still disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Syneos Health
- Principal Investigator
- Nicholas Farinola, B.Sc (Biomed. Sci.),BMBS,FRACPCMAX Clinical Research
- Intervention
- APB-R3(drug)
- Enrollment
- 31 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2023 – 2023
Study locations (1)
- CMAX Clinical Research, Adelaide, South Australia, Australia
Collaborators
AprilBio Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05715736 on ClinicalTrials.govOther trials for Adult-onset Still disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07203001A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's DiseaseNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE3NCT05814159A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)Swedish Orphan Biovitrum
- RECRUITINGNCT04402086Rheumatology Patient Registry and BiorepositoryYale University
- RECRUITINGNCT03510442Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related ConditionsNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- RECRUITINGNCT05927454Acostill ( RaDiCo Cohort) (RaDiCo Acostill)Institut National de la Santé Et de la Recherche Médicale, France
- RECRUITINGNCT02143986Glycosylated Ferritin in Macrophagic Activation SyndromesBrugmann University Hospital